
    
      The drug being tested in this study is called TAK-536TCH. TAK-536TCH is being tested to treat
      people who have essential hypertension. The study looked at effectiveness and long-term
      safety of TAK-536TCH in people who took TAK-536CCB in addition to standard care.

      The study enrolled 341 patients. Participants received:

        -  TAK-536CCB (as TAK-536/AML, 20 mg/5 mg) in run-in period,

        -  TAK-536TCH (as TAK-536/ AML/HCTZ, 20 mg/5 mg/12.5 mg) in treatment period

        -  TAK-536CCB and HCTZ 12.5 mg in treatment period

      All participants were asked to take tablets at the same time each day throughout the study.

      This multi-center trial was conducted in Japan. The overall time to participate in this study
      was 56 weeks (4 weeks run-in period and 52 weeks treatment period). Participants made
      multiple visits to the clinic during the study.
    
  